DIASTAT ACUDIAL (diazepam) by Bausch + Lomb. Approved for benzodiazepine [epc]. First approved in 1997.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
DIASTAT ACUDIAL is a rectal gel formulation of diazepam, a benzodiazepine approved in 1997 for acute seizure management and alcohol withdrawal syndrome. It works by enhancing GABA-mediated inhibition at GABA-A receptors in the central nervous system, suppressing excessive neuronal depolarization that generates and spreads seizures. The rectal delivery route provides rapid, non-invasive access for acute seizure intervention.
Minimal commercial activity and approaching loss of exclusivity indicate a niche, cost-managed product with limited team expansion opportunities.
Benzodiazepine
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
Worked on DIASTAT ACUDIAL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDIASTAT ACUDIAL offers minimal career growth opportunities given its approaching LOE status, niche market position, and minimal clinical pipeline. Roles focus on maintaining legacy brand presence and managing reimbursement in a competitive, commoditizing market rather than driving strategic innovation.